GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life sciences clusters. Yet that has not stopped several other regions from trying to carve out their own piece of the life science pie. Recently the commercial real estate firm Jones Lang LaSalle identified nine emerging regions: Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis. While the first three are pretty established, a stronger case can be made for the rest as emerging clusters. As active as all have been, however, they remain overshadowed by San Francisco Bay Area as well as Boston and Cambridge. Do you think any of the newly identified regions will outpace its established rivals?